Bertrand Cariou
Centre National de la Recherche Scientifique(FR)Centre National de la Recherche Scientifique(FR)Inserm(FR)Inserm(FR)École Normale Supérieure - PSL(FR)Centre Hospitalier Universitaire de Nantes(FR)Centre d'Investigation Clinique de Nantes(FR)Laboratoire de Physique de l'Ecole Normale Supérieure(FR)Institut du Thorax(FR)Nantes Université(FR)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Diabetes, Cardiovascular Risks, and Lipoproteins
Most-Cited Works
- → Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation(2009)1,613 cited
- → Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study(2020)834 cited
- → PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial(2014)742 cited
- → The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice(2006)538 cited
- → Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease(2013)482 cited
- → Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial